Cozad Asset Management Inc. Has $1.12 Million Holdings in Pfizer Inc. (NYSE:PFE)

Cozad Asset Management Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,832 shares of the biopharmaceutical company’s stock after selling 1,747 shares during the quarter. Cozad Asset Management Inc.’s holdings in Pfizer were worth $1,118,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Arcadia Investment Management Corp MI raised its stake in shares of Pfizer by 9.5% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 11,545 shares of the biopharmaceutical company’s stock valued at $383,000 after buying an additional 1,000 shares in the last quarter. Innova Wealth Partners bought a new stake in Pfizer during the 3rd quarter worth about $208,000. Busey Trust CO grew its holdings in Pfizer by 1.1% during the 3rd quarter. Busey Trust CO now owns 668,948 shares of the biopharmaceutical company’s stock worth $22,189,000 after acquiring an additional 7,527 shares during the last quarter. Toews Corp ADV bought a new stake in Pfizer during the 3rd quarter worth about $813,000. Finally, Accurate Wealth Management LLC grew its holdings in Pfizer by 7.5% during the 3rd quarter. Accurate Wealth Management LLC now owns 35,396 shares of the biopharmaceutical company’s stock worth $1,159,000 after acquiring an additional 2,467 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $25.61 on Wednesday. The company has a market capitalization of $145.02 billion, a price-to-earnings ratio of 71.14, a P/E/G ratio of 1.16 and a beta of 0.61. The firm’s 50 day simple moving average is $26.88 and its 200 day simple moving average is $28.26. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $40.37.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period last year, the company posted $1.14 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.56%. Pfizer’s dividend payout ratio (DPR) is currently 466.67%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on PFE shares. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $36.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.